ASND
Ascendis Pharma AS
Ascendis Pharma AS historical holders
total: 2
Polen Capital Management Ascendis Pharma AS transactions over time
- Total transactions:
- 4
- New positions:
- 1
- Added:
- 2
- Reduced:
- 1
- Held since:
- 2025 Q2
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q1
Polen Capital Management has been an institutional investor in Ascendis Pharma AS (ASND) since 2025 Q2. According to 2026 Q1 report, Polen Capital Management holds 1,812 shares with a market value of roughly $414.46K representing 0.00% of their equity portfolio. The fund/company first acquired ASND in 2025 Q2, initially purchasing 2,719 shares. Since the initial investment, Polen Capital Management has made 3 more transactions in this position.
Does Polen Capital Management still hold ASND?
Yes, Polen Capital Management continues to hold Ascendis Pharma AS (ASND). According to their 2026 Q1 report, they maintain a position of 1,812 shares valued at approximately $414.46K, representing 0.00% of their equity portfolio.
When did Polen Capital Management first invest in ASND?
Polen Capital Management first invested in Ascendis Pharma AS (ASND) in 2025 Q2 at the reported quarter-end price of $172.60 per share, acquiring 2,719 shares in their initial purchase.
What is Polen Capital Management's average cost basis for ASND?
Based on historical transaction data, Polen Capital Management's estimated cost basis for Ascendis Pharma AS (ASND) is approximately $182.99 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $182.98
- Weighted AVG sell price:
- $213.24
ASND transactions history by Polen Capital Management
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
1,812
|
$228.73
|
$414,459
|
+49.63% (+601)
|
+0%
|
|
2025 Q4
|
0.00%
|
1,211
|
$213.24
|
$258,234
|
-56.22% (-1,555)
|
-0%
|
|
2025 Q3
|
0.00%
|
2,766
|
$198.81
|
$549,908
|
+1.73% (+47)
|
+0%
|
|
2025 Q2
|
0.00%
|
2,719
|
$172.60
|
$469,299
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.